Wednesday, 13 Dec 2017

You are here

IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases

A registry based study has shown higher rates of immune mediated diseases (IMD) in patients with inflammatory bowel disease (IBD).

Researchers examined 47325 IBD patients from the Danish National Patient Registry and compared them to controls from a civilian registry and used ICD 10 codes to identify the diagnoses observed.

Overall they found 20 different IMDs were found to be significantly more frequent in the IBD group - 16 associated with ulcerative colitis (UC) and 12 with Crohns disease (CD).  Having IBD showed significantly increased ORs of having:

  • primary sclerosing cholangitis (PSC),
  • celiac disease,
  • type 1 diabetes (T1D),
  • sarcoidosis,
  • asthma,
  • iridocyclitis,
  • psoriasis,
  • pyoderma gangrenosum,
  • rheumatoid arthritis,
  • ankylosing spondylitis.

Disorders seen predominantly with UC  were autoimmune hepatitis, primary biliary cholangitis, Grave's disease, polymyalgia rheumatica, temporal arteritis , and atrophic gastritis.

Restricted to CD were psoriatic arthritis and episcleritis.

Restricted to women with UC were atrophic gastritis, rheumatoid arthritis, temporal arteritis, and polymyalgia rheumatica.

Restricted to women with CD were episcleritis, rheumatoid arthritis, and psoriatic arthritis.

The only disease restricted to men was sarcoidosis.

Considerable overlap exists between these IMDs and IBD.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Skin Remission in Dermatomyositis is Uncommon

JAMA Dermatology reports that clinical remission was relatively uncommon in dermatomyositis, despite aggressive systemic therapy, but was best in those receiving mycophenolate during a 3-year study.

Pregnancy Outcomes Worse with Myopathies

Women with the autoimmune inflammatory myopathies dermatomyositis (DM) and polymyositis (PM) are at increased risk for hypertensive disorders in pregnancy, a nationwide retrospective study found.

Health Economics of SLE

A number of presentations over the past few days have addressed the health economics of SLE.

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (abstract 6L). Ustekinumab is an IL12/23 agent already approved for use in psoriasis, psoriatic arthritis and Cohn’s disease.

EULAR/ACR SLE Classification Criteria Update

Today the draft of the new EULAR/ACR lupus classification criteria was presented at the ACR 2017.